/Healthcare%20researchers%20working%20in%20medical%20lab%20by%20chokniti%20via%20Adobe%20Stock.jpeg)
Danish pharmaceutical giant Novo Nordisk (NVO) might not be a household name, but its flagship products have probably been lighting up your socials for a while now. We’re specifically talking about Ozempic and Wegovy, which have become part of a daily routine for around 100 million people worldwide.
Nobody can deny these weight-loss wonder drugs have made a considerable impact on people's lives, and they’re likely alleviating a lot of pressure on healthcare systems around the world. But Novo has a growing direct-to-consumer business, and every market has a saturation point.
